Birth weight affects final height in patients treated for growth hormone deficiency

E Cacciari1, S Zucchini, A Cicognani

  • 1First Paediatric Clinic, University of Bologna, Bologna, Italy. ped1@alma.unibo.it

Clinical Endocrinology
|January 5, 2000
PubMed

Insights

Birth weight significantly impacts final height in children treated for growth hormone (GH) deficiency. Those born small for gestational age (GA) achieved lower final heights compared to appropriate or large for GA individuals.

Area of Science:

  • Pediatric Endocrinology
  • Growth and Development

Background:

  • Birth weight is a known factor influencing postnatal growth and initial response to growth hormone (GH) therapy in GH-deficient individuals.
  • However, the precise relationship between birth weight and final height outcomes in these patients remains unclear.

Purpose of the Study:

  • To investigate the association between birth weight status (small, appropriate, or large for gestational age) and final height achieved after GH therapy in children with GH deficiency.

Main Methods:

  • A retrospective study analyzed 108 patients with idiopathic and isolated GH deficiency treated with human GH (hGH).
  • Patients were categorized based on birth weight for gestational age: small (n=24), appropriate (n=77), and large (n=7).
  • Final height was assessed after 33-96 months of hGH treatment at a dose of 20 U/m2/week.

Main Results:

  • Patients born small for gestational age (GA) achieved significantly lower final height standard deviation scores (SDS) compared to appropriate and large for GA groups (-1.71 vs. -1.14 and -0.70 SDS, respectively).
  • The height SDS increment from therapy initiation to final height was also significantly lower in the small for GA group (0.54) compared to the appropriate (0.99) and large (1.49) for GA groups.
  • A higher percentage of large for GA individuals reached above their target height (71%) compared to appropriate (38%) and small for GA (21%) groups. A positive correlation was observed between birth weight and final height (r=0.38).

Conclusions:

  • Birth weight is a significant determinant of final height outcomes in children with GH deficiency, even when treated with GH therapy.
  • Individuals born small for GA experience a disadvantage in achieving final height, while those born large for GA appear to benefit.
  • These findings underscore the importance of considering birth weight status when predicting and managing growth outcomes in GH-deficient children.
Abstract

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Physical Growth During Infancy and Toddlerhood01:18

Physical Growth During Infancy and Toddlerhood

Physical growth is especially rapid during the first three years of life, with the greatest rate in the first few months after birth. Although children continue to gain height and weight throughout infancy and toddlerhood, the rate of growth gradually slows during the second and third years. At most ages, boys are typically slightly taller and heavier than girls, reflecting a common pattern of early physical development.Changes in Body ProportionsAs infants become toddlers, their body...
Signs of Puberty01:27

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
Polygenic Traits01:35

Polygenic Traits

When more than one gene is responsible for a given phenotype, the trait is considered polygenic. Human height is a polygenic trait. Studies have uncovered hundreds of loci that influence height, and there are believed to be many more. Due to the high number of genes involved, as well as environmental and nutritional factors, height varies significantly within a given population. The distribution of height forms a bell-shaped curve, with relatively few individuals in the population at the...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...